

## Cambodia : Cambodia Rapid Immunization Support Project

### 1. Project Information

Project ID:	P000521	Instrument ID:	L0521A
Member:	Cambodia	Region:	South-Eastern Asia
Sector:	CRF-Public Health	Sub-sector:	N/A
Instrument type:	<input checked="" type="checkbox"/> Loan:50.00 US Dollar million <input type="checkbox"/> Guarantee	Lead Co-financier(s):	Asian Development Bank
ES category:	C	Borrowing Entity:	Ministry of Economy and Finance, Cambodia
Implementing Entity:	Ministry of Health, Cambodia		
Project Team Leader:	Ankur Agrawal		
Responsible DG:	Rajat Misra		
Responsible Department:	INF1		
Project Team Members:	Yang Shuai, OSD - Environment & Social Development Specialist; Jinghui Li, Team Member; Bernardita Saez, Project Counsel; Liu Yang, Alternate Counsel; Shodi Nazarov, OSD - Financial Management Specialist; Rabindra Shah, OSD - Procurement Specialist; Jinghui Li, Project admin		
Completed Site Visits by AIIB:	Mar, 2023 ADB and AIIB conducted virtual implementation support mission in March, 2023		
Planned Site Visits by AIIB:	Sep, 2023 Next mission is being planned in November, 2023.		
Current Red Flags Assigned:	1		
Current Monitoring Regime:	Regular Monitoring		
Previous Red Flags Assigned:	1		
Previous Red Flags Assigned Date:	2023/03		

### 2. Project Summary and Objectives

The objective of the Project is to increase access to eligible COVID-19 vaccines for target population groups in Cambodia.

The Project will support the procurement of 14.5 million doses safe and effective vaccines against COVID-19. It will contribute to the government's goal of strengthening population immunity by providing booster doses and primary vaccination to children below 5 years of age. The Project is co-financed with the Asian Development Bank (ADB) under its rapid response component of ADB's Asia Pacific Vaccine Access Facility (APVAX).

The total Project cost is USD 153.5 million, for which AIIB finances USD50 million (32.57 percent), ADB finances USD95 million (61.89 percent) and the Government of Cambodia (GoC) finances the remaining USD8.5 million (5.54 percent). The loan proceeds from AIIB and ADB will finance expenditures relating to the procurement of COVID-19 vaccines that meet the APVAX eligibility criteria. The GoC contribution will cover financing charges, personnel

expenditure and vaccine storage and transportation expenses.

### 3. Key Dates

Approval:	Mar. 24, 2022	Signing:	Apr. 22, 2022
Effective:	Sep. 29, 2022	Restructured (if any):	
Orig. Closing:	Dec. 31, 2024	Rev. Closing (if any):	

### 4. Disbursement Summary (USD million)

Contract Awarded:		Cancellation (if any):	0.00
Disbursed:	14.27	Most recent disbursement (amount/date):	14.27/Mar. 03, 2023
Undisbursed:	35.73	Disbursement Ratio (%) <sup>1</sup> :	28.55

### 5. Project Implementation Update

A total amount of USD14.27 million (28.6% of loan amount) has been disbursed through retroactive financing. Given the evolution in the global Covid-19 pandemic situation, GoC had earlier confirmed that procurement of Covid-19 vaccines was not envisaged and expressed interest to restructure the Project to incorporate Project Investment Component under ADB's APVAX.

Components	Physical Progress	Environmental & Social Compliance	Procurement
Procurement of eligible COVID-19 vaccines	The retroactive financing of ADB and AIIB has been used to support the roll-out of 6 million doses, through a 2-dose primary vaccination series to approximately 3 million people.	Since the project has been categorized as C for all E&S aspects under ADB's Safeguard Policy Statement (SPS), no standalone safeguards monitoring report is required. Regulations and technical guidelines are in place for collection, storage, treatment, and disposal of medical waste, overseen by the ministries of environment and health. Current and planned arrangements for the collection, transportation, treatment, and disposal of incremental medical waste were reviewed during the due diligence and confirmed to be acceptable. A summary of safeguards compliance with supporting documents pertaining to adequacy of COVID-19 immunization waste management	A total of 6 million doses have been procured till now - 2 million doses under AIIB financing and 4 million doses under ADB financing.

<sup>1</sup> Disbursement Ratio is defined as the volume (e.g. the dollar amount) of total disbursed amount as a percentage of the net committed volume.

---

		system will be provided in the consolidated annual reports which is due and is expected in Q4 2023.	
--	--	---	--

---

**Financial Management:**

Annual audited project financial statement (APFS) for FY2022 was due for submission on June 30, 2023, however no disbursements were made in the year 2022. Therefore, the audit for the period from the signing date to December 31, 2022 will be waived by both Banks and the revised first project audit period will be from the signing date to December 31, 2023. The revised project audit is due for submission by June 30, 2024. The status of the financial management action plan was due in March 2023 but the same is yet to be submitted. The FM aspects for the restructuring proposal will be discussed during the upcoming mission in November 2023.

---

**6. Status of the Grievance Redress Mechanism (GRM)**

A GRM exists at the Government of Cambodia (<https://moh.gov.kh/?lang=en>) which is able to receive and address complaints.

---

**7. Results Monitoring (please refer to the full RMF, which can be found on the last page of this PIMR)**

Initial results from vaccine procurement are updated.

---

**Remarks:**

---

Project Indicators	Objective	Indicator level	Unit of Measure	Cumulative Target Values										Frequency	Responsibility	Comments				
				Baseline		2022		2023		2024		End Target								
				Year	Value	Target	Actual	Target	Actual	Target	Actual	Year	Target				Actual			
Additional 10.12 million people in target populations vaccinated or boosted against COVID-19, disaggregated by sex		Project	Number	2022	17 million	17 million	23.1					27.12				27.12 million		Once	Ministry of Health	

Project Intermediate Indicators	Indicator level	Unit of Measure	Cumulative Target Values													Frequency	Responsibility	Comments	
			Baseline		2021		2022		2023		2024		2025		End Target				
			Year	Value	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Year				Target